BioSpace News Archive

According to Report, the gene therapy market growth is expanding at a registered CAGR of 20.2% during the forecast period and to reach valuation US$ 13 billion by 2029.

As per Precedence Research, The healthcare information systems market size is expected to surpass around US$ 487.8 billion by 2030 and expanding growth at a CAGR of 7.8% from 2022 to 2030.

Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.

The National Cancer Institute-designated Albert Einstein Cancer Center has announced the appointment of three faculty members to key leadership positions, reflecting the center’s commitment to basic science, translational, and clinical research and its core principles of diversity, equity, and inclusion.

Seno Medical’s Imagio® Breast Imaging System has been named a finalist in the 2022 Medical Device Excellence Awards, in the Radiological, Imaging, and Electromechanical Devices category.

GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant health, is proud to welcome Barney Graham, MD, PhD., to its Human Health Scientific Advisory Board.

ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to the Bio-HDL CER-001 for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiency.

BioCopy AG introduces ValidaTe, an innovative, proprietary platform based on microarrays for the highly parallelized screening of drug candidates for T-cell therapy.

Alcami, a U.S.-based pharmaceutical contract development and manufacturing organization, announced plans to expand its biostorage footprint at Masy BioServices.

Over three days, the patients will receive three intravenous doses of the drug and their clinical progress, as well as the development of the inflammatory process.